The discovery and optimization of a novel series of BRS-3 agonists are described. We explored a potent BRS-3 agonist with low brain penetration to avoid an adverse effect derived from central nervous system exposure. Through the derivatization process, chiral diazepines 9f and 9g were identified as possessing low brain penetration as well as potent in vitro activity against human and mouse BRS-3s.
Keywords: Bombesin receptor subtype-3 (BRS-3) agonists; Brain penetration; Diazepine.
Copyright © 2014 Elsevier Ltd. All rights reserved.